253 related articles for article (PubMed ID: 16026266)
21. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
Brogard JM; Caro-Sampara F; Blicklé JF
Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879
[TBL] [Abstract][Full Text] [Related]
22. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
ElGamal H; Munusamy S
Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
[TBL] [Abstract][Full Text] [Related]
23. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
Huang Q; Liu Q; Ouyang D
Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
[TBL] [Abstract][Full Text] [Related]
24. Molecular targets of diabetic cardiovascular complications.
Ahmad FK; He Z; King GL
Curr Drug Targets; 2005 Jun; 6(4):487-94. PubMed ID: 16026267
[TBL] [Abstract][Full Text] [Related]
25. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
Hamada Y; Nakamura J
Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
[TBL] [Abstract][Full Text] [Related]
26. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Kador PF; Wyman M; Oates PJ
Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
[TBL] [Abstract][Full Text] [Related]
27. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
Bhadada SV; Vyas VK; Goyal RK
Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
[TBL] [Abstract][Full Text] [Related]
28. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
Gries FA
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S201-7. PubMed ID: 8529515
[TBL] [Abstract][Full Text] [Related]
29. Aldose reductase, still a compelling target for diabetic neuropathy.
Oates PJ
Curr Drug Targets; 2008 Jan; 9(1):14-36. PubMed ID: 18220710
[TBL] [Abstract][Full Text] [Related]
30. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
Kovacikova L; Prnova MS; Majekova M; Bohac A; Karasu C; Stefek M
Molecules; 2021 May; 26(10):. PubMed ID: 34066081
[TBL] [Abstract][Full Text] [Related]
31. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
Bosquet F; Grimaldi A
Presse Med; 1986 May; 15(19):879-83. PubMed ID: 3012508
[TBL] [Abstract][Full Text] [Related]
32. New therapies for the chronic complications of older diabetic patients.
Clements RS
Am J Med; 1986 May; 80(5A):54-60. PubMed ID: 3085495
[TBL] [Abstract][Full Text] [Related]
33. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
Park HK; Ahn CW; Lee GT; Kim SJ; Song YD; Lim SK; Kim KR; Huh KB; Lee HC
Diabetes Res Clin Pract; 2002 Feb; 55(2):151-7. PubMed ID: 11796181
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors].
Wajchenberg BL
Rev Assoc Med Bras (1992); 1996; 42(2):63-5. PubMed ID: 9110450
[No Abstract] [Full Text] [Related]
35. The pharmacology of aldose reductase inhibitors.
Kador PF; Robison WG; Kinoshita JH
Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
[No Abstract] [Full Text] [Related]
36. Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions.
Sonowal H; Ramana KV
Curr Med Chem; 2021; 28(19):3683-3712. PubMed ID: 33109031
[TBL] [Abstract][Full Text] [Related]
37. Focus on molecules: aldose reductase.
Anil Kumar P; Bhanuprakash Reddy G
Exp Eye Res; 2007 Dec; 85(6):739-40. PubMed ID: 16997295
[No Abstract] [Full Text] [Related]
38. Relationship between aldose reductase enzyme and the signaling pathway of protein kinase C in an in vitro diabetic retinopathy model.
Sarikaya M; Yazihan N; Daş Evcimen N
Can J Physiol Pharmacol; 2020 Apr; 98(4):243-251. PubMed ID: 31743046
[TBL] [Abstract][Full Text] [Related]
39. Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
Robison WG
Adv Exp Med Biol; 1988; 246():365-72. PubMed ID: 3150650
[TBL] [Abstract][Full Text] [Related]
40. Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.
Masson EA; Boulton AJ
Drugs; 1990 Feb; 39(2):190-202. PubMed ID: 2109678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
